A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme

Phase 1 Completed 24 enrolled University of Alabama at Birmingham

NaSingle-groupOpen-labelTreatment

Summary

To determine the maximum tolerated dose of ABT 510 when administered concurrent with radiation therapy for patients with newly diagnosed glioblastoma multiforme.

Timeline

Start: 2003-08
Primary completion: 2008-07
Completion: 2008-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ABT-510	Peptide	20 mg	Subcutaneous

A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme

Summary

Timeline

Drugs

Indications